FLEXI

Main information

  • Trade name:
  • FLEXI 10 CAP
  • Dosage:
  • 750,400;MG
  • Pharmaceutical form:
  • CAP
  • Composition:
  • 10
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • FLEXI 10 CAP
    India
  • Language:
  • English

Other information

Status

  • Source:
  • Central Drugs Standard Control Organization
  • Last update:
  • 09-08-2016

13-11-2018

Registration Reminder: FDA Center for Veterinary Medicine Public Webinar about Genome Editing in Animals on Dec. 3

Registration Reminder: FDA Center for Veterinary Medicine Public Webinar about Genome Editing in Animals on Dec. 3

On Dec. 3, 2018, FDA’s Center for Veterinary Medicine (CVM) will hold a public webinar about genome editing in animals, focusing mainly on current scientific evidence, promising uses of this technology in animals, the potential risks & CVM’s flexible, risk-based approach to regulation.

FDA - U.S. Food and Drug Administration

12-11-2018

Minister Bruno Bruins ondertekent actieplan ambulancezorg

Minister Bruno Bruins ondertekent actieplan ambulancezorg

Minister Bruno Bruins (Medische Zorg), Ambulancezorg Nederland (AZN) en Zorgverzekeraars Nederland (ZN) presenteerden vandaag het actieplan ambulancezorg. Het actieplan bevat verbeteringen waarmee ambulancezorg efficiënter kan worden ingezet en waarmee de opleiding en inzet van personeel in de regio’s gestroomlijnd wordt. Ook is er aandacht voor het aantrekkelijker maken van de vakopleiding. Door meer flexibiliteit in de bekostiging van ambulancezorg wordt het makkelijker om maatwerk te leveren in de reg...

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

9-11-2018

Sargassum seaweed: limit the exposure of residents and workers to hydrogen sulphide

Sargassum seaweed: limit the exposure of residents and workers to hydrogen sulphide

Since August 2014, the French Caribbean and French Guiana have been experiencing successive waves of Sargassum seaweed washing up on their coastlines. Despite the efforts made to clean it up, the seaweed decomposes in situ. This leads to the production of hydrogen sulphide (H2S), which can sometimes be detected at high concentrations. Doctors' reports concerning the health effects suffered by people exposed to H2S, and complaints from the general public relating to the problem of odours, have increased s...

France - Agence Nationale du Médicament Vétérinaire

18-10-2018

Unauthorized "Surfaz-SN Triple Action Cream" seized from Mississauga store may pose serious health risks

Unauthorized "Surfaz-SN Triple Action Cream" seized from Mississauga store may pose serious health risks

Health Canada seized “Surfaz-SN Triple Action Cream”—an unauthorized skin cream promoted for antifungal, antibacterial and anti-inflammatory use—because it is labelled to contain prescription drugs (betamethasone dipropionate and neomycin sulphate). The product was seized from Kaf African Caribbean Market (2642 Liruma Road, Unit 2A) in Mississauga, Ontario.

Health Canada

11-10-2018

Wild boar in focus: Review of existing models on spatial distribution and density of wild boar and proposal for next steps

Wild boar in focus: Review of existing models on spatial distribution and density of wild boar and proposal for next steps

Published on: Wed, 10 Oct 2018 00:00:00 +0200 This report provides a review of existing models for predicting the spatial distribution and abundance of wild boar at various scales (global, continental, national and regional) in order to inform the development of a new model to produce estimates of wild boar abundance at European level. The review identifies and discusses a range of models based on a wide variety of data types, corresponding to those targeted by the data collection model set by ENETwild,...

Europe - EFSA - European Food Safety Authority Publications

18-9-2018

Les Distributions Orca Lite Inc. recalls FLEXI LIGHT multi-purpose utility lighters

Les Distributions Orca Lite Inc. recalls FLEXI LIGHT multi-purpose utility lighters

Health Canada's sampling and evaluation program has determined that these lighters do not meet the Lighters Regulations in Canada and may pose a fire or burn hazard. Specifically, the child-resistant mechanism may not work properly.

Health Canada

6-9-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on an updated approach for including added sugar information on the Nutrition Facts labels of pure maple syrup and honey

Statement from FDA Commissioner Scott Gottlieb, M.D., on an updated approach for including added sugar information on the Nutrition Facts labels of pure maple syrup and honey

Proposed rule revises front of package calorie labeling requirements to provide more flexibility to industry

FDA - U.S. Food and Drug Administration

7-8-2018

Voluntary Recall Notice of El Guapo Jamaica Hibiscus Flower Pouches Due to Unlabeled Peanut Allergen

Voluntary Recall Notice of El Guapo Jamaica Hibiscus Flower Pouches Due to Unlabeled Peanut Allergen

Mojave Foods Corporation is initiating a voluntary recall of four sizes of El Guapo Jamaica Hibiscus Flower packages in flexible packaging due to an unlabeled peanut allergen

FDA - U.S. Food and Drug Administration

26-6-2018

Home Hardware Stores Ltd. recalls Home Flexible Multi-Purpose Lighter

Home Hardware Stores Ltd. recalls Home Flexible Multi-Purpose Lighter

Health Canada's sampling and evaluation program has determined that these lighters do not meet the Lighters Regulations in Canada and may pose a fire or burn hazard. Specifically the lighters:

Health Canada

22-6-2018

Kabinet wil mensen kansen geven op werk, ontwikkeling en invloed

Kabinet wil mensen kansen geven op werk, ontwikkeling en invloed

De samenleving verandert door globalisering, technologische vooruitgang en flexibilisering. Sommige mensen varen daar wel bij, anderen raken achterop. Het kabinet vindt het belangrijk dat iedereen in de samenleving kan blijven meedoen. Daarom moeten mensen meer kansen krijgen: om zich te ontwikkelen, op de arbeidsmarkt, en om hun eigen omgeving te beïnvloeden. Dit schrijft minister Koolmees van Sociale Zaken en Werkgelegenheid aan de Tweede Kamer, mede namens de ministers van Onderwijs, Cultuur en Wetens...

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

4-10-2011

The reimbursement for glucosamine is removed on 28 November 2011

The reimbursement for glucosamine is removed on 28 November 2011

The Reimbursement Committee and the Danish Medicines Agency have reassessed the reimbursement status of glucosamine-containing medicines. We have decided to remove the reimbursement for these over-the-counter medicines on 28 November 2011. Glucosamine is used for the alleviation of painful osteoarthritis.

Danish Medicines Agency

20-9-2011

Consultation responses on the Reimbursement Committee’s recommendation concerning the reimbursement status of glucosamine-containing medicines

Consultation responses on the Reimbursement Committee’s recommendation concerning the reimbursement status of glucosamine-containing medicines

The Reimbursement Committee’s recommendation on the future reimbursement status of glucosamine-containing medicines was open for consultation until 8 August 2011. The Danish Medicines Agency received 4 consultation responses.

Danish Medicines Agency

27-5-2011

Consultation on the Reimbursement Committee's recommendation for glucosamine

Consultation on the Reimbursement Committee's recommendation for glucosamine

The Reimbursement Committee has reassessed the reimbursement status of glucosamine-containing medicines. Glucosamine-containing medicines are used for the alleviation of painful osteoarthritis. The Reimbursement Committee recommends removing general conditional reimbursement for these medicines.

Danish Medicines Agency

3-3-2011

The Danish Medicines Agency begins ad hoc reassessment of reimbursement status of glucosamine (M01AX05)

The Danish Medicines Agency begins ad hoc reassessment of reimbursement status of glucosamine (M01AX05)

Clinical studies have called into question the efficacy of glucosamine for the alleviation of painful osteoarthritis. This has contributed to the Danish Medicines Agency’s decision to initiate ad hoc reassessment of glucosamine-containing medicines, which today have general conditional reimbursement when prescribed for the alleviation of symptoms of mild to moderate osteoarthritis and when prescribed to old-age pensioners.

Danish Medicines Agency

19-6-2018

Aerinaze (Merck Sharp and Dohme Limited)

Aerinaze (Merck Sharp and Dohme Limited)

Aerinaze (Active substance: desloratadine; pseudoephedrine sulphate) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3930 of Tue, 19 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/772/T/37

Europe -DG Health and Food Safety